StockMarketWire.com - Antibiotics developer Motif Bio said it would commence a study to evaluate the effectiveness of a treatment candidate against Listeria.

Motif Bio said it would utilise NIAID's suite of preclinical services through JMI Laboratories to evaluate iclaprim against the gram-positive bacteria, which causes food-borne, life-threatening infections.

Listeriosis was a rare but serious infection usually caused by eating food, such as cheese and other dairy products, deli meat and produce that has been contaminated with L. monocytogenes.

'Listeriosis is a potentially life-threatening infection for which more effective treatment options are needed,' chief medical officer David Huang said.

'If the results of this study confirm that iclaprim has potent activity against L. monocytogenes, we believe that iclaprim could be a potentially useful treatment option and would warrant further study.'




Story provided by StockMarketWire.com